Vaniqa Rx Facial Hair Remover May Be Strong OTC Switch Candidate
This article was originally published in The Rose Sheet
Executive Summary
Ongoing studies on Bristol-Myers Squibb's newly approved Vaniqa prescription hair removal drug could broaden the target consumer of the topical cream to include men. FDA approved the product for removal of women's facial hair July 27.
You may also be interested in...
OTC Vaniqa Could Surface By Early 2005
Women First HealthCare may explore Rx-to-OTC switch opportunities forVaniqa facial hair growth retardation cream as early as 2004, the firm stated
OTC Vaniqa Could Surface By Early 2005
Women First HealthCare may explore Rx-to-OTC switch opportunities forVaniqa facial hair growth retardation cream as early as 2004, the firm stated
Vaniqa
Second round of national TV ads launching now and print ads debuting in April focus on educating women who remove unwanted facial hair rather than building brand awareness as the first campaign did, Bristol Myers Squibb said during Feb. 22 press event. Co-marketed by Gillette, Rx topical cream (13.9% eflornithine) debuted in September (1"The Rose Sheet" Aug. 7, 2000, p. 6). Second round of ads will feature close-up shots of women applying the cream and an illustration of how product effects the hair follicle